NO20003565D0 - Sulfonylaminoderivater som hemmer matriks-nedbrytende metalloproteinaser - Google Patents

Sulfonylaminoderivater som hemmer matriks-nedbrytende metalloproteinaser

Info

Publication number
NO20003565D0
NO20003565D0 NO20003565A NO20003565A NO20003565D0 NO 20003565 D0 NO20003565 D0 NO 20003565D0 NO 20003565 A NO20003565 A NO 20003565A NO 20003565 A NO20003565 A NO 20003565A NO 20003565 D0 NO20003565 D0 NO 20003565D0
Authority
NO
Norway
Prior art keywords
inhibit matrix
degrading metalloproteinases
sulfonylamino derivatives
sulfonylamino
derivatives
Prior art date
Application number
NO20003565A
Other languages
English (en)
Other versions
NO20003565L (no
NO317977B1 (no
Inventor
Paivi Jaana Kukkola
Leslie Anne Robinson
Junichi Sakaki
Motowo Nakajima
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20003565D0 publication Critical patent/NO20003565D0/no
Publication of NO20003565L publication Critical patent/NO20003565L/no
Publication of NO317977B1 publication Critical patent/NO317977B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO20003565A 1998-02-04 2000-07-11 Sulfonylaminoderivater som hemmer matriks-nedbrytende metalloproteinaser NO317977B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1881998A 1998-02-04 1998-02-04
PCT/EP1999/000646 WO1999042443A1 (en) 1998-02-04 1999-02-02 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases

Publications (3)

Publication Number Publication Date
NO20003565D0 true NO20003565D0 (no) 2000-07-11
NO20003565L NO20003565L (no) 2000-10-03
NO317977B1 NO317977B1 (no) 2005-01-17

Family

ID=21789936

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003565A NO317977B1 (no) 1998-02-04 2000-07-11 Sulfonylaminoderivater som hemmer matriks-nedbrytende metalloproteinaser

Country Status (18)

Country Link
US (1) US6277987B1 (no)
EP (2) EP1053226A1 (no)
JP (1) JP4750272B2 (no)
KR (1) KR20010040698A (no)
CN (1) CN1195735C (no)
AU (1) AU747911B2 (no)
BR (1) BR9909322A (no)
CA (1) CA2318145C (no)
HU (1) HUP0101176A3 (no)
ID (1) ID24957A (no)
IL (1) IL137465A0 (no)
NO (1) NO317977B1 (no)
NZ (1) NZ505968A (no)
PL (1) PL342009A1 (no)
RU (1) RU2208609C2 (no)
SK (1) SK11692000A3 (no)
TR (1) TR200002224T2 (no)
WO (1) WO1999042443A1 (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2217418C2 (ru) * 1998-04-03 2003-11-27 Санкио Компани, Лимитед Сульфонамидное производное, лекарственное средство, способы лечения
SK12462001A3 (sk) 1999-03-03 2002-04-04 The Procter & Gamble Company Inhibítory metaloproteáz
KR20010102486A (ko) * 1999-03-03 2001-11-15 데이비드 엠 모이어 알케닐- 및 알키닐-함유 메탈로프로테아제 저해제
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
EP1088815A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
AU7450300A (en) * 1999-09-29 2001-04-30 Sankyo Company Limited Sulfonamide derivatives
RU2245876C2 (ru) 2000-03-21 2005-02-10 Дзе Проктер Энд Гэмбл Компани Производные сульфонамидов и фармацевтическая композиция на их основе
CA2401728A1 (en) 2000-03-21 2001-09-27 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
PL357250A1 (en) * 2000-03-21 2004-07-26 The Procter & Gamble Company Heterocyclic side chain containing metalloprotease inhibitors
JP2003528074A (ja) * 2000-03-24 2003-09-24 メチルジーン インコーポレイテッド ヒストン脱アセチル化酵素の阻害剤
AU4882101A (en) * 2000-04-28 2001-11-12 Shionogi & Co., Ltd. Mmp-12 inhibitors
EP1174129A1 (en) * 2000-07-17 2002-01-23 Zenner, Hans Peter, Prof. Dr. med. Use of a matrix-metalloprotease inhibitor for the treatment of cancer
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
WO2003051825A1 (en) * 2001-12-14 2003-06-26 Exelixis, Inc. Human adam-10 inhibitors
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
TW200305396A (en) * 2002-03-27 2003-11-01 Shionogi & Co Cartilage extracellular matrix degradation
JP4002927B2 (ja) 2002-05-29 2007-11-07 メルク エンド カムパニー インコーポレーテッド 炭疸病治療および致死因子阻害に有用な化合物
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
CA2566191A1 (en) 2004-05-11 2005-12-15 Merck & Co., Inc. Process for making n-sulfonated-amino acid derivatives
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US20080187508A1 (en) * 2004-09-08 2008-08-07 Boys Town National Research Hospital Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12
US20100003276A1 (en) * 2004-12-07 2010-01-07 Hermes Jeffery D Methods for treating anthrax and inhibiting lethal factor
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
US7576222B2 (en) * 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
US20100247512A1 (en) * 2006-03-31 2010-09-30 The Regents Of The University Of Michigan Pericellular Collagenase Directs the 3-Dimensional Development of White Adipose Tissue
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
EP1972617A1 (en) * 2007-03-19 2008-09-24 Bracco Imaging, S.P.A. Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
ES2524259T3 (es) * 2008-03-24 2014-12-04 Novartis Ag Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
EP2149568A1 (en) 2008-07-22 2010-02-03 Bracco Imaging S.p.A Aryl-sulphonamidic dimers as metalloproteases inhibitors
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ614305A (en) * 2008-12-05 2015-03-27 Abbvie Inc Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
ITTO20090648A1 (it) * 2009-08-19 2011-02-20 Istituto Naz Per La Ricerca Sul Cancro Inibitori di adam17 atti a modulare il rilascio di alcam (cd166) solubile in cellule tumorali e loro uso nel trattamento terapeutico del carcinoma ovarico epiteliale (eoc)
US9023318B2 (en) 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
HUE057569T2 (hu) 2014-12-17 2022-05-28 Pimco 2664 Ltd N-(4-hidroxi-4-metil-ciklohexil)-4-fenil-benzolszulfonamid és N-(4-hidroxi-4-metil-ciklohexil)-4-(2-piridil)-benzolszulfonamid vegyületek és terápiás alkalmazásuk
CN110483437B (zh) * 2018-05-14 2022-12-06 嘉兴维眸生物科技有限公司 一种含五元环的化合物及其制备和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1493664A1 (de) 1964-07-16 1969-06-04 Hoechst Ag Verfahren zur Spaltung von aromatischen Sulfonsaeureamiden
GB9027426D0 (en) * 1990-12-18 1991-02-06 Sandoz Ltd Improvements in or relating to organic compounds
AU653279B2 (en) * 1991-12-30 1994-09-22 Sanofi Novel 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
EP0639982A1 (en) 1992-05-01 1995-03-01 British Biotech Pharmaceuticals Limited Use of mmp inhibitors
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
AU690703B2 (en) 1994-06-22 1998-04-30 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
SK282833B6 (sk) 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
US5753653A (en) 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
EA003294B1 (ru) 1995-12-08 2003-04-24 Агурон Фармасьютикалс, Инк. Ингибиторы металлопротеиназы, фармацевтические композиции, их содержащие, и их фармацевтические применения
NZ325939A (en) * 1996-01-23 2000-06-23 Shionogi & Co Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives
CZ294063B6 (cs) * 1996-05-17 2004-09-15 Warner-Lambert Company Bifenylsulfonamid, jeho použití a farmaceutický prostředek s jeho obsahem
JPH10265452A (ja) 1996-05-24 1998-10-06 Ono Pharmaceut Co Ltd フェニルスルホンアミド誘導体
HUP0000505A3 (en) 1996-08-28 2001-12-28 Procter & Gamble Saturated 7-9 membered heterocyclic n-hydroxycarboxamide derivatives and pharmaceutical compositions containing them
BR9713465A (pt) 1996-08-28 2000-03-28 Procter & Gamble Inibidores metalotprotease de amina cìclica sibstituìda
TR199900429T2 (xx) 1996-08-28 1999-05-21 The Procter & Gamble Company Spirosiklik metaloproteaz inhibit�rleri.
CN1228771A (zh) 1996-08-28 1999-09-15 普罗克特和甘保尔公司 1,3-二杂环金属蛋白酶抑制剂
BR9712792A (pt) 1996-08-28 1999-12-14 Procter & Gamble Inibidores de metaloprotease bidentada.
ATE226573T1 (de) 1996-08-28 2002-11-15 Procter & Gamble Heterozyklische metalloproteaseinhibitoren
BR9714142A (pt) * 1996-12-17 2000-02-29 Warner Lambert Co Uso de inibidores de metaloproteìnases matriciais para tratamento de distúrbios neurológicos e promoção de cicatrização de feridas
AU720615B2 (en) * 1997-01-17 2000-06-08 Pharmacia & Upjohn Company Bis-sulfonomides hydroxamic acids as MMP inhibitors
EP0973748A1 (en) 1997-04-01 2000-01-26 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
AU7294098A (en) 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DE19719428A1 (de) 1997-05-12 1998-11-19 Hoechst Ag Substituierte Diaminocarbonsäuren
ATE210639T1 (de) 1997-05-09 2001-12-15 Hoechst Ag Substituierte diaminocarbonsäuren
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
DE19719585A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Substituierte Diaminocarbonsäuren
ID24105A (id) 1997-07-22 2000-07-06 Shionogi & Co Komposisi untuk mengobati atau mencegah glomerulopati
CN1265647A (zh) * 1997-07-31 2000-09-06 普罗克特和甘保尔公司 无环金属蛋白酶抑制剂

Also Published As

Publication number Publication date
AU747911B2 (en) 2002-05-30
JP4750272B2 (ja) 2011-08-17
BR9909322A (pt) 2000-12-05
US6277987B1 (en) 2001-08-21
IL137465A0 (en) 2001-07-24
CA2318145C (en) 2009-10-27
ID24957A (id) 2000-08-31
CA2318145A1 (en) 1999-08-26
CN1290250A (zh) 2001-04-04
EP1918278A1 (en) 2008-05-07
KR20010040698A (ko) 2001-05-15
EP1053226A1 (en) 2000-11-22
TR200002224T2 (tr) 2000-12-21
NZ505968A (en) 2003-03-28
NO20003565L (no) 2000-10-03
HUP0101176A3 (en) 2002-06-28
HUP0101176A2 (hu) 2001-09-28
SK11692000A3 (sk) 2001-02-12
RU2208609C2 (ru) 2003-07-20
JP2002503720A (ja) 2002-02-05
WO1999042443A1 (en) 1999-08-26
CN1195735C (zh) 2005-04-06
AU2923599A (en) 1999-09-06
PL342009A1 (en) 2001-05-07
NO317977B1 (no) 2005-01-17

Similar Documents

Publication Publication Date Title
NO20003565L (no) Sulfonylaminoderivater som hemmer matriks-nedbrytende metalloproteinaser
NO20015477L (no) 4,5,6,7-tetrahydroindazolderivater som antitumormidler
NO20002173L (no) Pleuromutilin-derivater som antimikrobielle midler
NO20004159D0 (no) 2-pyridylmetylaminderivater for anvendelse som fungicider
PT1175408E (pt) Derivados sulfonamida
DK0933372T3 (da) Sulfonamidderivater som prodrugs for aspartylproteaseinhibitorer
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
EE200200069A (et) Metalloproteinaaside inhibiitoriteks olevad pürimidiin-3,4,6-trioonid
ID26829A (id) Turunan-turunan sulfonamida
DE69942123D1 (de) FACTOR VIIa INHIBITORE
NO20043099L (no) Azaindolylalkylamin-derivater som 5-hydroksytryptamin-6-ligander
DE69900356D1 (de) Nitro-Isoharnstoffderivate
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
DE69908446D1 (de) Programmfehlerbeseitigung
ATE321042T1 (de) Piperazin-derivate
ATE229503T1 (de) Cyclohexandiol-derivate
DK1075471T3 (da) Idolylderivater som serotonerge midler
DE69907845D1 (de) Sulfonamid-Derivate
ID27766A (id) Garam-garam paroksetin
FI990227L (fi) Paperinvalmistuksen lisäaine
DK1121349T3 (da) Substituerede thiadiazolsulfonamider som interleukin-1-beta-inhibitorer
EE200100017A (et) N-tert-butüülhüdroksüülamiini uued soolad
NO20011654D0 (no) Benzamidderivater som trombininhibitorer
DK1073651T3 (da) Indolylderivater som serotonerge midler
DK1077945T3 (da) Isoquinoliner som urokinaseinhibitorer

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees